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Abstract
Background/Aim: As Thai people living with HIV/AIDS gain increasing access to antiretroviral (ARV) therapy, it is
important to evaluate the impact this has not only on clinical outcomes, but also on patients’ functional status and
well-being. In this study, we translated, culturally adapted and tested the reliability and validity of two widely-used
health-related quality of life questionnaires - the MOS-HIV Health Survey and the SF-12 - in people living with HIV/
AIDS in Northern Thailand. Methods: Questionnaires were administered to 100 patients at community hospital
outpatient ARV clinics in northern Thailand. Reliability was estimated using Cronbach’s alpha, while evidence for
validity was tested using known-groups comparison based on CD4 group, symptom distress score, bed days and
days of reduced activity in the past three months.
Results: Patients’ median age was 36, with 58% female, 58% working as laborers, and 60% completing at least
primary education. Median CD4 count was 218 cells/mm
3. There were no missing data. For the MOS-HIV and SF-
12, mean physical summary scores were 53.1 and 49.0 respectively; mean mental summary scores were 53.4 and
45.6, respectively. Internal consistency coefficients were >0.7 for all but one scale, the PF scale (0.67). As
hypothesized, scores were slightly to moderately correlated with CD4 count, symptom score, number of days in
bed or with reduced activity. Correlations were higher with physical health scores than with mental health scales.
The MOS-HIV discriminated clinical known groups slightly better than the SF-12.
Conclusion: Both the MOS-HIV and the shorter SF-12 were successfully adapted for people with HIV/AIDS in
Northern Thailand, and showed encouraging evidence for reliability and validity. These patient reported
questionnaires could be valuable tools in evaluating therapeutic interventions and other innovations in health and
social services, and to estimate health needs and population disability related to HIV.
Introduction
With the introduction of generic antiretroviral therapy
into the world market, the number of people accessing
antiretroviral therapy globally continues to rise. Access
to appropriate antiretroviral therapy offers hope for
decreased morbidity and mortality to those living with
HIV/AIDS. However, leaders of multi-national trials
have cautioned against defining success by using only
clinical endpoints such as lab results (CD4+ T lympho-
cyte count, HIV viral load) as these measures cannot
capture the complexity of a patient’s experience on anti-
retroviral treatment [1,2]. To achieve comprehensive
evaluation, health-related quality of life (HRQOL) mea-
sures have become increasingly important to help assess
the impact treatment has on patients’ lives.
Thailand has often been held up as a model for effec-
tive HIV control and prevention in low and middle
income countries. Thailand has a strong health systems
infrastructure and is also a regional hub for pharmaceu-
tical production [3]. Because of this, Thailand was able
to guarantee universal access to antiretroviral treatment
through the National Access to Antiretroviral for People
Living with HIV/AIDS (NAPHA) program, passed in
2001 [4]. With the scale-up of antiretroviral (ARV)
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to access antiretroviral treatment. Furthermore, patients
have been able to remain on treatment longer than they
might have otherwise because of the ability of physicians
to switch regimens under the NAPHA plan. According
to the Global Fund, in 2008 more than 140,000 people
were receiving on ARV in Thailand [5]; however,
HRQOL has rarely been assessed in the Thai setting
outside of clinical trials. To accomplish this, it is neces-
sary to identify HRQOL measures that are reliable, cul-
turally appropriate and conceptually equivalent to
existing measures. This will allow interpretation of the
r e s u l t sf r o mT h a is t u d i e s ,a sw e l la sc o m p a r i s o nt o
other studies both within country and globally.
A number of health-related quality of life measures
have been developed for HIV-infected patients and
include assessment of various domains, including func-
tional status and psychological well-being [6,7]. The
purpose of this study was to translate, culturally adapt,
and test the reliability and validity of two widely-used
HRQOL measures, the Medical Outcomes Study-HIV
(MOS-HIV) and Short Form Health Survey-12 (SF-12),
among Thai people living with HIV/AIDS currently or
previously on HAART. A third tool, the AIDS Clinical
Trials Group (ACTG) symptom distress module (SDM)
[8] was also translated and culturally adapted into Thai
and pilot tested among the same group of patients. In
addition to estimating the reliability of the instruments,
we also compared their ability to discriminate known
groups based on CD4 count, symptom distress score,
number of days spent in bed and number of days where
activity had to be reduced due to health status.
Methods
The study design included two phases: translation/cultural
adaptation and pilot testing. During the first stage, the
MOS-HIV, SF-12, and ACTG SDM were translated and
culturally adapted from the original US English into Thai.
In the second stage, these questionnaires were used in a
cross-sectional survey of HIV+ patients on HAART in two
community-based district hospitals in Northern Thailand.
Questionnaires
The MOS-HIV and SF-12 were culturally adapted and
translated using the linguistic validation method devel-
oped by the MAPI Research Institute [9]. This method
aims to achieve conceptual equivalence rather than lit-
eral translation and has been used successfully to trans-
late many patient-reported outcome instruments into a
variety of languages.
The MOS-HIV is a 35 item questionnaire that was
specifically designed to measure QOL in patients with
HIV. The MOS-HIV has two summary scores for men-
tal and physical health, and 10 subscales which include
the following dimensions: general health perceptions,
pain, physical functioning, role functioning, social func-
tioning, cognitive functioning, mental health, vitality
(energy/fatigue), health distress and quality of life [10].
The SF-12 is a brief, generic 12-item questionnaire. It
assesses eight dimensions of HRQOL: physical function-
ing, role limitations due to physical health, role limita-
tions due to emotional health, social functioning, bodily
pain, general health perceptions, vitality, and mental
health(4). Two summary scores are generated - a physi-
cal component score (PCS) and a mental component
score (MCS)[10].
The AIDS Clinical Trials Group (ACTG) Symptom
Distress Module (SDM) is a patient-reported index that
asks the patient to state whether he/she has a symptom
and then to quantify how much that symptom bothers
him or her [11]. Responses are quantified on a Likert-
type scale with response items ranging from 0 (I do not
have this symptom) to 4 (I have this symptom, and it is
a big problem for me). The 22 items within the symp-
tom score address an array of issues, including sleep,
appetite, depression, weight, and sexual dysfunction that
are not captured in many traditional QOL measures.
Higher symptom scores indicate both an increased inci-
dence in symptoms as well as a larger negative effect
these symptoms have on the patient’s QOL.
MAPI method of translation/cultural adaptation
The MAPI method of linguistic validation comprises
three major steps: 1) forward translation from the
source, or original, language into the target language (in
this case, Thai), 2) backward translation, and 3) patient
testing. This method is similar to the one used by the
International Quality of Life Assessment (IQOLA) pro-
ject, which translated and culturally adapted the SF-36,
SF-12, and SF-8 into more than 40 languages [9,11,12].
In the first step, two independent translators produce
their own forward translated versions of the instrument.
All parts of the questionnaire are translated, including
instructions for completing the questionnaire, original
questions, and response items. Once the two indepen-
dent versions are completed, each version is back-trans-
lated into the source language by two separate
translators. Finally, a harmonized version is formulated.
This harmonized version attempts to reconcile differ-
ences between the two versions and incorporates input
and feedback from both translators, disease-specific spe-
cialists, and other members of the research team. In our
study, the study team, comprised of researchers, nurses,
and community advisory board members reviewed the
concepts related to health-related quality of life, and
then discussed each instrument question-by-question to
ensure that consensus was reached on the cultural valid-
ity and fidelity of the translated version.
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variations of concepts (such as emotions) that were difficult
to translate, or activities that are common in the West but
not relevant to life in Thailand. For example, in the MOS-
HIV, ‘down in the dumps’ was translated to mean ‘really
depressed.’ Translators also had difficulty with some English
idioms such as ‘weighed down by health problems,’ which
was originally inappropriately translated to mean ‘losing
weight due to health problems’. The final version used a
Thai translation to ‘be burdened by health’. In the SF-12, it
was necessary to emphasize the words ‘physical’ and ‘mental’
in questions such as ‘accomplished less because of your phy-
sical health’ or ‘accomplished less because of mental state’ to
clarify the separate domains of health being asked about.
Finally, both questionnaires had difficulty with the English
concept ‘peaceful’ or ‘calm’, which was ultimately translated
as being ‘stable, feel OK’ ("nim” in Thai).
Regarding activities present in both questionnaires
Thai translators and research team members noted that
climbing several flights of sta i r s ,b o w l i n g ,a n dw a l k i n g
one block were not relevant in Thai society. Most Thai
cities or villages do not have standard city blocks and
some villages do not have buildings with many stairs, so
it is difficult for Thai people to quantify what one flight
of stairs is. Also, bowlingi sa nu n c o m m o np a s tt i m e .
Instead of being translated literally, the translation and
research team agreed upon equivalent activities. For
example, ‘walking one block’ became ‘walking from one
electric pole to the next’ and ‘climbing several flights of
stairs’ became ‘walking up a hill.’
T h ef i n a li n s t r u m e n t sw e r ea g r e e du p o nb ya l lp a r t i e s
before being pilot tested among HIV+ patients at outpa-
tient clinics in Northern Thailand.
Subjects
T h et a r g e ts a m p l ef o rt h ep i l o ts t u d yw a s1 0 0H I V +
patients receiving ARV at two local HIV outpatient hos-
pital clinics in northern Thailand.
Interviewers approached consecutive patients after
they had completed their appointments with health care
personnel and invited them to participate. If they
agreed, the interviewers attempted to obtain informed
consent. Inclusion criteria for participation in the study
consisted of: age 20 years or older, current or past use
of HAART, ability to communicate in Thai, and ability
to provide consent. Non-Thai speaking patients and
patients unable to complete an interview due to
impaired mental status were excluded. Five patients
declined to participate in the study due to lack of time,
transportation issues, or lack of interest in the study.
Demographic and HIV/AIDS related information
Demographic information, including age, sex, marital
status, educational attainment, and occupation/
employment status were collected from each patient.
Patients were also asked to report the date and results
of their last CD4 cell count. In addition, each patient
was asked to estimate the number of days in the past
three months that illness had kept him or her in bed
(bed days). A second question asked about the number
of days in the past three months that the patient was
required to reduce his or her daily activities due to
illness.
Procedures
Each patient completed either the MOS-HIV or the SF-
12. All patients completed the symptom questionnaire.
A mediated self-administration technique was suggested
and used to administer the interviews. Interviewers sat
side by side with the patients and read questions out
loud to the patient while the patient read along with the
interviewer using his or her own copy of the question-
naire. The patient then filled in his or her response on
his or her personal copy of the questionnaire.
Statistical Analysis
Chi-square and T-tests were used to compare character-
istics of patients in the two samples. Scale distributions
for each scale score within the MOS-HIV and SF-12
and the proportion of minimum and maximum
responses were determined to assess the impact of floor
and ceiling effects for each scale.
The reliability, or scale internal consistency, of both
questionnaires was evaluated by calculating Cronbach’s
alpha for the multi-item scales. In our study, a Cron-
bach’s alpha of 0.7 or greater was considered accepta-
ble for group comparisons. Known groups validity
testing was also conducted for the summary scores of
the SF-12 and MOS-HIV using a series of dichoto-
mized variables for CD4 count, SDM score, number of
bed days, and number of days of reduced activity. CD4
count was dichotomized at the approximate median
(200 cells/mm3); symptom score was also dichoto-
mized at the median (13.0). Bed days and number of
days of reduced activity were dichotomized as zero
days vs. any (one or more) days. We hypothesized that
the mean summary scores for both the SF-12 and
MOS-HIV would be weakly to moderately correlated
with each variable.
Results
Participant Characteristics
Overall
Of the 100 pilot test participants, the majority were
female (58.0%), married (53.0%), employed as laborers
(57.3%), and had completed only primary education
(60.0%). The participants’ median age was 36 years, as
shown in Table 1.
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QOL tool Group Total
Characteristics
MOS-HIV (n = 50) SF12 (n = 50) (N = 100)
Count Col % Count Col % Count Col %
Sex Male 17 34.0% 25 50.0% 42 42.0%
Female 33 66.0% 25 50.0% 58 58.0%
Marital status Single 2 4.0% 8 16.0% 10 10.0%
Married* 22 44.0% 31 62.0% 53 53.0%
Widowed* 24 48.0% 9 18.0% 33 33.0%
Divorced 2 4.0% 2 4.0% 4 4.0%
Education Primary education 30 60.0% 30 60.0% 60 60.0%
Middle School 6 12.0% 7 14.0% 13 13.0%
High School 9 18.0% 6 12.0% 15 15.0%
Vocational Ed 4 8.0% 5 10.0% 9 9.0%
Bachelor degree 1 2.0% 2 4.0% 3 3.0%
Occupation Manual Labor 26 52.0% 23 46.0% 49 49.0%
Agriculture 3 6.0% 5 10.0% 8 8.0%
Office work 2 4.0% 3 6.0% 5 5.0%
Self employed 5 10.0% 10 20.0% 15 15.0%
Government employee & State Enterprise 1 2.0% 2 4.0% 3 3.0%
House work 4 8.0% 3 6.0% 7 7.0%
Unemployed 9 18.0% 4 8.0% 13 13.0%
ART Taken No 2 4.0% 2 2.0%
Yes 50 100.0% 48 96.0% 98 98.0%
Age Median 35.5 36 36
Mean ± SD 36.3 ± 5.7 37.9 ± 8.1 37.1 ± 7.0
Min - Max 26 - 51 26 - 64 26 - 64
(n = 40) (n = 42) (N = 82)
CD4 cell count 0 - 100 11 27.5% 8 19.0% 19 23.2%
101 - 200 14 35.0% 13 31.0% 27 32.9%
201 - 300 7 17.5% 10 23.8% 17 20.7%
301 - 500 7 17.5% 7 16.7% 14 17.1%
> 500 1 2.5% 4 9.5% 5 6.1%
Median 142.0 209.0 174.5
Mean ± SD 189.25 ± 138.80 246.00 ± 177.50 218.32 ± 161.36
Min - Max 0 -550 17 - 700 0 - 700
Signs and Symptoms
Score (0 - 88)
Median 15.0 10.50 13.0
Mean ± SD 16.70 ± 11.17 13.72 ± 10.47 15.21 ± 10.88
Min - Max 1 - 61 0 - 51 0 - 61
Number of days spent in
bed in past 3 months
None 38 76.0% 40 80.0% 78 78.0%
1 - 2 days 6 12.0% 5 10.0% 11 11.0%
> 2 days 6 12.0% 5 10.0 11 11.0%
Number of days of
reduced activity due to
illness in past 3 months
None 40 80.0% 39 78.0% 79 79.0%
1 - 2 days 1 2.0% 4 8.0% 5 5.0%
> 2 days 9 18.0% 7 14.0% 16 16.0%
*chi-square, p < 0.05
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161.4 cells/mm
3, with a median of 2.9 months since the
most recent CD4 test. The majority of patients (76.8%)
reported CD4 counts less than or equal to 300, with the
greatest number of participants (32.9%) reporting counts
between 101-200.
Patient Characteristics by questionnaire module
Table 1 provides participant characteristics stratified by
q u a l i t yo fl i f eb a t t e r yc o m p l e t e d .T h e r ew e r es i g n i f i -
cantly more married patients in the SF-12 group and
widowed patients in the MOS-HIV group. Otherwise
there were no statistically significant differences between
the groups. Participants completing the MOS-HIV had a
median age of 35.5 years, compared to the median age
of 36.0 years for those completing the SF-12. Those who
completed the MOS-HIV were predominately female
(66%). SF-12 respondents were divided equally between
males and females. Proportionately, respondents to each
questionnaire had approximately the same educational
attainment with 60.0% of those completing each QOL
battery having finished at least primary education. The
majority of individuals - 58.0% of those completing the
MOS-HIV and 56.0% of those completing the SF-12-
earned their livelihoods through farming or manual
labor. Just under half (48%) of those completing the
MOS-HIV were widowed and 44% were married. The
majority (62%) of those completing the SF-12 were mar-
ried, with 18% being widowed.
The mean self-reported CD4 cell count was 189.3 ±
138.8 cells/mm
3 for respondents to the MOS-HIV and
246.0 ± 177.5 cells/mm
3 for respondents to the SF-12.
Psychometric Properties
The median times to complete the quality of life com-
ponents alone were 11.0 minutes to complete the MOS-
HIV and 5.0 minutes to complete the SF-12. The
response rate for both the MOS-HIV and SF-12 was
100%, with no missing answers for any of the questions.
The symptom score questionnaire also had a very high
response rate, with only 1% missing data for each item.
Compared to the MOS-HIV and SF-12, there was a
more skewed distribution towards the lower end of the
scale, with a majority of participants responding, “No, I
do not experience this symptom.”
Scale Distributions
The mean and median summary and subscale scores of
each of the QoL questionnaires are given in Table 2.
MOS-HIV
The mean physical health summary score (PHS) was
53.1 and the mental health summary score (MHS) was
53.4. Very limited floor effects were found in the MOS-
HIV, with 2.0% of the participants providing the lowest
possible score for the social functioning (SF) subscale.
Ceiling effects were more pronounced. The only sub-
scale that had 0% of respondents providing the highest
possible score was the general health perceptions (GHP)
subscale. The remaining ten scales ranged from 6.0%
(energy/fatigue, vitality [EF]) to 76.0% (role functioning
[RF]) of the respondents reporting the highest possible
score of 100.
SF-12
T h em e a nP C Sw a s4 9a n dt h em e a nM C Sw a s4 5 . 6 .
There were no floor or ceiling effects found for the SF-
12 summary score during this pilot test.
Evidence for Reliability
The internal consistency coefficients for the multi-item
scales are shown in Table 3. Cronbach’s alpha coeffi-
cients were greater than 0.7 for all of the scales of the
MOS-HIV, except for the physical functioning (PF) sub-
scale, which approached acceptability at 0.67. Since sub-
scale scores are not generated for the SF-12, alpha
coefficients were not estimated.
Evidence for validity
Table 4 shows correlations of the MOS-HIV and SF-12
questionnaire subscale scores with patient-reported
CD4, symptom score, number of days spent in bed, and
number of reduced activity. As hypothesized, symptom
score, number of days spent in bed, and number of days
of reduced activity were all negatively correlated with
subscale scores. This provides evidence for the construct
validity of the subscales as a measure of health status.
Known groups validity testing was done to compare
the SF-12 and MOS-HIV physical and mental health
summary scores to variables measuring health status.
These variables included CD4 count, symptom score,
number of days spent in bed, and number of days of
reduced activity. F-scores were calculated using ANOVA
of differences between each scale and each variable.
For CD4 group, neither the MOS-HIV or SF-12
achieved significance for discrimination between the
groups. The p-values for the MOS-HIV were slightly
smaller than those for the SF-12 (MOS-HIV PHS = 0.29
vs. SF-12 PCS = 0.51; MOS-HIV MHS p = 0.20 vs. SF-
12 MCS p = 0.84).
Both the MOS-HIV and SF-12 scales were successful
at discriminating between these groups with all sum-
mary scores’ reaching significance (MOS-HIV PHS p =
0.002, MOS-HIV MHS p = 0.001, SF-12 PCS p =.015,
and SF-12 MCS p = 0.00)
Only the PHS score discriminate number of days of
reduced activity (0 days vs. any days, p = 0). P-values for
other comparisons were PCS (p = 0.082), MHS (p =
0.097), and MCS (0.633).
Both the MOS-HIV and SF-12 physical health sum-
mary scores were able to discriminate groups defined by
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Subscale Number of items Mean Median SD a 25% 75% % Floor % Ceiling
MOS-HIV
Physical Health Summary Score (PHS) n/a 53.1 54.6 7.2 0.54 50.28 58.91 0 0
Mental Health Summary Score (MHS n/a 53.4 54.9 7 0.51 48.31 58.01 0 0
General Health 5 56.8 60 15.3 0.46 48.75 65 0 0
Pain 2 74.2 77.8 20.5 0.6 55.56 100 0 26
Physical Function 6 88.7 91.7 17.2 0.78 83.33 100 0 48
Role Function 2 88 100 21.6 NC 87.5 100 0 76
Social Function 1 84.8 100 27.6 NC 80 100 2 70
Mental Health 5 74.9 76 15.7 0.67 64 84 0 10
Energy & Fatigue (Vitality) 4 73.2 75 16.2 0.63 63.75 85 0 6
Health Distress 4 82.4 87.5 17.7 0.83 73.75 100 0 26
Cognitive Function 4 78.7 80 16.3 0.65 68.75 91.25 0 12
Quality of Life 1 80 75 16.8 *** 75 100 0 30
Health Transition 1 72 75 24.6 *** 50 100 0 38
SF-12
Physical Health Summary Score (PCS) n/a 49.03 49.58 7.5 *** 44.78 54.93 0 0
Mental Health Summary Score (MCS) n/a 45.63 46.28 9.1 *** 39.01 51.65 0 0
Table 3 Inter-correlation among mean scale scores and Cronbach’s alpha coefficients, MOS-HIV
Scale Mean score PHS MHS PF SF RF CF P MH EF HD QL GHP HT
PHS 53.1 0.76
MHS 53.4 0.56 0.76
PF 88.7 0.83 0.48 0.67
SF 84.8 0.69 0.47 0.39 0.77
RF 88.0 0.72 0.41 0.70 0.37 0.76
CF 78.7 0.42 0.48 0.37 0.32 0.25 0.77
P 74.2 0.53 0.35 0.31 0.11 0.13 0.27 0.78
MH 74.9 0.24 0.79 0.25 0.19 0.21 0.12 0.32 0.77
EF 73.2 0.62 0.79 0.61 0.31 0.44 0.33 0.37 0.52 0.75
HD 82.4 0.29 0.81 0.18 0.28 0.18 0.35 0.40 0.65 0.52 0.76
QL 80.0 0.55 0.67 0.59 0.33 0.45 0.20 0.15 0.33 0.67 0.32 —
GHP 56.8 0.60 0.53 0.33 0.34 0.41 0.08 0.43 0.40 0.45 0.34 0.40 0.76
HT 72.0 0.27 0.17 0.27 0.28 0.17 0.10 -0.12 -0.11 0.15 -0.01 0.44 0.23 —
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days vs. any days). The p-values for the PHS and PCS
were 0.001 and 0.003 respectively: MHS and MCS were
not significant (0.092 and 0.104 respectively).
Discussion
The results of this initial test provide evidence for
acceptable reliability and validity of the Thai versions of
the MOS-HIV and SF-12 as measures of HRQOL
among HIV+ patients in Northern Thailand. Both ques-
tionnaires were successfully translated/culturally adapted
into the Thai language. The low refusal rate (4%) and
high response rate for all questionnaires (99-100%)
point to good acceptability by patients.
In this study, trained interviewers adopted a modified
face-to-face technique where the questionnaire was
read out-loud to the patient, with the patient then fill-
ing in his or her response. This modified technique
was well-received by both interviewers and intervie-
wees and allowed interviewees to ask questions or have
issues clarified during the interview process. By filling
out the answers themselves, however, confidentiality
was preserved. Furthermore, in Thai and other Asian
cultures, deference to authority (such as the inter-
viewer) and the desire to minimize interpersonal con-
flict may influence patient response in interviewer-
administration as interviewees will try to answer ques-
tions in a way they think will be socially acceptable to
the interviewer. Self-administering the questionnaires
m a yh a v ea l l o w e di n t e r v i e w e e st ob em o r et r u t h f u li n
their answers.
Psychometric performance was consistent with pre-
vious studies and suggested that there was adequate
internal consistency for the MOS-HIV [12-17]. Evidence
for construct validity was demonstrated by the relation-
ship between summary scores and relevant clinical vari-
ables, including symptom distress score, number of days
spent in bed, and days of reduced activity. Interestingly,
CD4 count was the only variable which was not signifi-
cantly correlated to either physical or mental health
summary scores. This is consistent with most previous
r e s e a r c hs t u d i e s[ 1 7 , 1 8 ]a n di su n s u r p r i s i n ga sm a n y
patients with low CD4 on HAART may be asympto-
matic, while some of those responding to treatment may
have diminished scores due to side effects of HAART
therapy. Also as expected, the physical health scores
were better able to distinguish between the variables
examined, which reflect physical rather than mental
functioning.
It was interesting to note that the MOS-HIV per-
formed slightly better than the SF-12 in its ability to dis-
criminate between known groups with a greater number
of significant p-values (4 vs. 3) and p-values approaching
significance. However, one must be cautious in inter-
preting these results, given the different samples of
patients completing the two questionnaires.
Because we were interested in the ultimate usability of
health-related quality of life questionnaires in clinical
settings, we selected tools that differed in length. The
more comprehensive MOS-HIV provides more precise
estimates of a range of specific issues. However, it is
more time-consuming than the SF-12 (11 vs 5 minutes
on average). Investigators and clinicians should weigh
these factors in selecting between the two alternatives.
A study published in 2004 evaluating the psychometric
properties of an independently translated version of the
MOS-HIV found a high level of internal consistency
reliability of multi-item scales with all multi-item scales
achieving Cronbach’s alpha of 0.7 or above [14]. In the
2004 study, respondents were recruited only from
PLWHA support or self-help groups. Our study was
conducted in community-based hospital settings and
recruited respondents from patients at their regular vis-
its, which may capture a more representative sample of
HIV+ people in Northern Thailand. Notably, many
patients had very low (<300) CD4 counts. However, the
overwhelming majority (98%) of patients participating in
our study were receiving antiretroviral therapy, which
was rare during the time of the study. At the time of
this study, there was no translated version of the SF-12
available. However, there is now an official translation
of this instrument. Future studies should be conducted
to confirm the performance of the SF-12 Thai version.
Table 4 Scale score correlations with patient reported
clinical markers
CD4 Symptom
score
Days spent in
bed
Days of reduced
activity
MOS-HIV
PHS 0.18 -0.58 -0.68 -0.41
MHS 0.25 -0.63 -0.41 -0.18
GHP 0.19 -0.43 -0.13 -0.18
BP 0.55 -0.51 -0.44 -0.43
PF 0.30 -0.48 -0.74 -0.46
RF 0.26 -0.44 -0.53 -0.26
SF -0.04 -0.39 -0.40 -0.09
MH 0.25 -0.51 -0.26 -0.23
EF 0.32 -0.41 -0.48 -0.29
HD 0.07 -0.53 -0.32 -0.06
CF 0.14 -0.49 -0.36 -0.05
QL 0.22 -0.37 -0.31 -0.19
HT -0.03 -0.14 -0.12 0.16
SF-12
PCS 0.11 -0.39 -0.36 -0.38
MCS -0.05 -0.55 -0.57 -0.10
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for responsiveness, as all questionnaires were tested
among patients at a single time point. Since patients
completed either the MOS-HIV or the SF-12 and not
both, we were unable to perform head-to-head compari-
sons of the two instruments or correlate them to each
other. Although our study indicated that the MOS-HIV
performed slightly better than the SF-12 in its ability to
discriminate between known groups, this could be a
random effect since different groups filled out different
questionnaires. In addition, because we did not have
access to patient medical records or providers, we asked
patients to self-report their CD4 count. There was indi-
vidual variability in the extent to which patients could
report these. However, we only used this variable to test
the construct validity of the quality of life scales. None-
theless, it is likely to have introduced additional random
error into the estimate of CD4 count and attenuated the
correlation with quality of life scores.
There is often little time in clinic settings for health
care personnel to administer questionnaires. Outside of
clinical trials, there is little attention paid to measure-
ments of HRQOL. However, more health care workers
are recognizing that HRQOL can play a large impact on
HIV treatment and care, especially in the area of com-
pliance with complicated and potentially toxic drug regi-
mens. As both questionnaires were well-accepted by
patients in this pilot test, in our own ongoing studies,
we are using the MOS-HIV at yearly intervals or at cer-
tain milestones in a patient’s care, such as immediately
before commencing antiretroviral therapy. At other vis-
its, a shorter tool, such as the SF-12 can provide a snap-
shot of the patient’sQ O L .B yf o c u s i n gap a r to ft h e
clinical encounter on QOL, the health care team is
given an opportunity to address issues that may not be
captured during a standard HIV clinic visit. Most
importantly, the patient is provided a dedicated outlet to
bring attention to concerns that may affect his or her
care with the team.
In conclusion, the Thai versions of the SF-12 and
MOS-HIV were acceptable, valid, and reliable among
HIV+ Thai patients interviewed in a clinical outpatient
setting. As more Thais are able to access ARV through
national health care programs designed to cover treat-
ment for PLWHA’s, attention to QOL will become
increasingly important to provide effective and patient-
centered care. The SF-12 and MOS-HIV are promising
tools that may be used in clinical environments to help
assess patient’s HRQOL and guide both patients’ and
providers’ decision-making.
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